Showing 2 results for Cinnarizine
Roya Salari, Hamed Hatefi, Elaheh Abbasi, Hamid-Reza Soltani-Gardefaramarzi, Mohammad-Hadi Mortazavi,
Volume 23, Issue 106 (11-2013)
Abstract
Background and purpose: Several studies have mentioned the prevalence of chronic tinnitus in the communities and its adverse effects on the patients’ quality of life. Although no cure for this condition has been found, the use of drugs, benzodiazepines and antihistamines, is common among the current treatments. This study compared the effects of alprazolam and cinnarizine therapy in patients with idiopathic tinnitus.
Materials and methods: This clinical trial study was done on 101 patients with idiopathic tinnitus. Patients were randomly divided into two groups and 15 days were treated with alprazolam and cinnarizine. The study data were analyzed using the SPSS software at the significant level of less than 0.05.
Results: Mean age of patients was 45.50 ± 12.40 years, ranged from 20 to 75 years. 67.3% (68) of patients were women and 32.7% (33) were men. The cure rate after treatment was 0% in alprazolam and 2.3% in cinnarizine groups, respectively. The rates of partial remission and drowsiness in alprazolam and cinnarizine groups were 47.7% and 43.2%, and 68.4% and 31.6%, respectively.
Conclusion: Alprazolam and cinnarizine are equally effective in the treatment of idiopathic tinnitus. Nevertheless, as the side effect of drowsiness was more in the alprazolam, it is preferable in terms of cinnarizine.
Pegah Katibeh, Rozita Bakhshizadeh Shirazi, Ramin Shiraly,
Volume 30, Issue 192 (1-2021)
Abstract
Background and purpose: Numerous drugs have been suggested to control pediatric migraine headaches, but there are limited numbers of randomized controlled trials to prove their efficacy. The aim of this study was to compare the efficacy of Propranolol + Cinnarizine and Propranolol + placebo in controlling migraine headaches in Children.
Materials and methods: A double-blind, placebo-controlled randomized clinical trial was performed in 90 eligible children aged 6-14 years of age attending Shiraz Imam Reza clinic, 2018. They were randomly assigned into either an intervention group (n=45) or a control group (n=45). Intervention group received Propranolol + Cinnarizine and control group received Propranolol + placebo. The frequency, duration, and severity of headaches were recorded for two months. Data analysis was carried out applying paired samples t-test and independent samples t-test.
Results: The mean age of children was 10 ± 2.6 years old. A positive family history of migraine was found in more than 70% of the participants. There was about 73% decrease in monthly mean frequency of headaches in both groups compared to baeline (reduction from 15 times to 4 times in intervention group and from 11 times to 3 times in control group). Also, mean duration and intensity of headaches decreased by 60% and 50%, respectively, in both groups compared to the baseline (P<0.001). There were no significant differences in mean frequency, duration, and severity of headaches within the first or second month between the two groups (P>0.12).
Conclusion: Combination of Propranolol and Cinnarizine showed no additional effect on controlling pediatric migraine headaches compared to Propranolol alone.
(Clinical Trials Registry Number: IRCT20180724040576N1)
